Product Name Idarubicin hydrochloride
Molecular Formula C26H28ClNO9
Molecular Weight 533.95
Application For research purpose only
Storage Store in a well-closed,light-resistant container
Custom synthesis Available
Idarubicin is an anthracycline cell cycle nonspecific anticancer agent that inhibits DNA synthesis, interferes with RNA polymerase, and inhibits topoisomerase ⅱ. Its potency was 8 times that of daunorubicin and 4 ~ 5 times that of doxorubicin. Idabicin hydrochloride is an anti-mitotic and cytotoxic agent. For the first-line treatment of adult acute non-lymphocytic leukemia (ANLL) and induction of remission in relapsed and refractory patients. Drugs are used as second-line treatment for acute lymphoblastic leukemia (ALL) in adults and children.
1. For the induction of remission of untreated acute non-lymphocytic leukemia in adults and the induction of remission of relapsed and refractory acute non-lymphocytic leukemia in adults.
2. Idabicin for injection is used in the second-line treatment of acute lymphoblastic leukemia in adults and children. Idabicin capsules are used for the first-line treatment of adult acute non-lymphocytic leukemia and for the treatment of patients with relapsed or refractory acute non-lymphocytic leukemia who cannot receive idabicin intravenously.
3. Also used in advanced breast cancer.
4. It is also used to treat myelodysplastic syndrome and non-Hodgkin's lymphoma.
September 16, 2021 5:12 am
December 31, 9999
September 16, 2021
Shijiazhuang City, Hebei Province, China
You must log in or register a new account in order to contact the publisher
Ibrutinib N-3 33079...